Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
Trial details
- Registry ID
- NCT00254202
- Phase
- Phase 3
The FDA approved Iloperidone (FANAPT®) on 6 May 2009.
Drug identity checked against registry records
Also recorded as FANAPT®; Fanapt®; VYV-683
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202 | Vanda Pharmaceuticals | Phase 3 | Completed | 2006-09-26Actual |
| Relapse Prevention Study in Patients With SchizophreniaNCT01291511 | Vanda Pharmaceuticals | Phase 3 | Completed | 2014-03Actual |
| Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderNCT04819776 | Vanda Pharmaceuticals | Phase 3 | Completed | 2022-09-07Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2009-05-06Day | Iloperidone | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA022192", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["FANAPT"], "active_ingredients": ["ILOPERIDONE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20090506", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |